Zobrazeno 1 - 10
of 50
pro vyhledávání: '"M V Taranova"'
Autor:
L Yu Milovanova, I A Dobrosmyslov, Yu S Milovanov, V V Fomin, M V Taranova, V V Kozlov, S Yu Milovanova, E I Kozevnikova
Publikováno v:
Терапевтический архив, Vol 90, Iss 6, Pp 48-54 (2018)
Aim of the study was to explore the role of the FGF-23/sKlotho/sclerostin ratio disturbance in the determining of cardiovascular risk in end stage renal disease (ESRD) patients, receiving treatment with regular hemodialysis (НD) or hemodiafiltration
Externí odkaz:
https://doaj.org/article/6dbeca9c0bd04b23b27d05d117b7b282
Autor:
Yu S Milovanov, I A Dobrosmyslov, S Yu Milovanova, M V Taranova, L Yu Milovanova, V V Fomin, V V Kozlov
Publikováno v:
Терапевтический архив, Vol 90, Iss 6, Pp 89-91 (2018)
The study demonstrated the results of the comparative analysis of various types of renal replacement therapy effects on the quality of life patients with terminal stage of chronic kidney disease on the basis of standardized questionnaires. It has bee
Externí odkaz:
https://doaj.org/article/cc242dfc855943a49b65529ddbbc8488
Publikováno v:
Терапевтический архив, Vol 88, Iss 4, Pp 105-111 (2016)
Heart injury is one of the extrahepatic manifestations of chronic hepatitis C (CHC). The paper gives Russian and foreign authors’ data on a relationship between CHC and myocardial injury. It discusses different pathogenetic components (the direct e
Externí odkaz:
https://doaj.org/article/472bd8f614f440a9ac47a3007f27f67d
Publikováno v:
Терапевтический архив, Vol 86, Iss 6, Pp 45-51 (2014)
AIM: To identify the risk factors of kidney injuries in hypertensive patients with uric acid (UA) metabolic disorders in order to choose the optimal management tactics, by analyzing the changes in markers for endothelial dysfunction (endothelin-1 (ET
Externí odkaz:
https://doaj.org/article/a8b9c876510f470191c22a2b1d7125d8
Autor:
S V Moiseev, P I Novikov, E N Semenkova, L A Strizhakov, S V Guliaev, T N Ianushkevich, N V Nikiforova, A D Meshkov, V V Panasiuk, Iu D Sorokin, M V Taranova, S A Parfenova, L V Dubrovskaia, E S Zhabina, E I Kuznetsova, I A Lopatina, N M Bulanov, N A Mukhin
Publikováno v:
Терапевтический архив, Vol 85, Iss 5, Pp 37-43 (2013)
AIM: To assess the risk of severe adverse events (AEs) within 6 months after treatment with biological agents in patients with rheumatic diseases (RD)/MATERIAL AND METHODS: The 6-month open-label trial included 107 patients with rheumatoid arthritis,
Externí odkaz:
https://doaj.org/article/5036bbf9a7c740e2b20f00cc162ea769
Autor:
S. Yu. Milovanova, L. V. Lysenko (Kozlovskaya), L. Yu. Milovanova, D. T. Abdurahmanov, M. V. Taranova, A. V. Volkov
Publikováno v:
Nephrology (Saint-Petersburg). 26:30-39
The review presents the main data on the problem of cryoglobulinemic vasculitis associated with HCV infection. The options for the course are considered, and modern diagnostic criteria, the choice of tactics, and the effectiveness of various treatmen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::113e5bd5f087979d51399b4951f06b9b
https://doi.org/10.36485/1561-6274-2022-26-3-30-39
https://doi.org/10.36485/1561-6274-2022-26-3-30-39
Autor:
Mikhail Ratanov, Vasiliy Kozlov, M V Taranova, Lidia Lysenko, V. D. Beketov, Alexey V Volkov, Svetlana Milovanova, Ludmila Milovanova, Anastasia I Pasechnik
Publikováno v:
International Urology and Nephrology. 54:1613-1621
BACKGROUND In chronic kidney disease (CKD) cardiovascular remodeling (CVR) is very frequent compared with general population and, as suppose, may be associated with «new» renal risk factors. The aim of study was to estimate association of new serum
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bdb43ca7d25e49ac81020ed0dddef34f
https://doi.org/10.1007/s11255-021-03046-8
https://doi.org/10.1007/s11255-021-03046-8
Autor:
A. A. Filippova, V. D. Beketov, A. I. Pasechnik, L Yu Milovanova, S Yu Milovanova, M V Taranova
Publikováno v:
Clinical Medicine (Russian Journal). 99:245-258
Сardiovascular disease (СVD) is the most common complication of chronic kidney disease (СKD). In patients with the earlier stages of CKD, the risk of death from CVD greatly exceeds the risk of progression to end-stage renal disease. In recent year
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::90590f632e5ef7664c22ccefb439f6c8
https://doi.org/10.30629/0023-2149-2021-99-4-245-258
https://doi.org/10.30629/0023-2149-2021-99-4-245-258
Autor:
M V Taranova, Ludmila Milovanova, Mikhail V. Kalashnikov, V. D. Beketov, Vladimir Reshetnikov, Anastasiia I. Pasechnik, Tatiana V. Androsova, V. V. Kozlov, Svetlana Milovanova
Publikováno v:
Терапевтический архив, Vol 93, Iss 6, Pp 679-684 (2021)
High risk of cardiovascular events is among leading problems in chronic kidney disease (CKD). Serum Klotho is supposed to be cardio- and nephroprotective; modification of its levels may be important in CKD.To evaluate the impact of vitamin D receptor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::21dd22f678e7904a9031c4feaa6966d1
https://ter-arkhiv.ru/0040-3660/article/viewFile/75948/56513
https://ter-arkhiv.ru/0040-3660/article/viewFile/75948/56513
Autor:
L Y Milovanova, L V Kozlovskaya, Vladimir Reshetnikov, M V Lebedeva, Svetlana Milovanova, M V Taranova, T V Androsova, Natalia Chebotareva, D O Zubacheva, Vasiliy Kozlov
Publikováno v:
Терапевтический архив, Vol 92, Iss 6, Pp 37-45 (2020)
Cardiovascular calcification (CVC) makes a significant contribution to the manifestation of cardiovascular complications in patients with chronic kidney disease. Early CVC markers are currently being actively studied to optimize cardio-renoprotective
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::793ab04c61e54db0d0031a22ffbd4725
https://doi.org/10.26442/00403660.2020.06.000670
https://doi.org/10.26442/00403660.2020.06.000670